Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

1.570 +0.030 (+1.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,398,984
Open 1.570
Bid (Size) 1.560 (1,048)
Ask (Size) 1.570 (82)
Prev. Close 1.540
Today's Range 1.490 - 1.610
52wk Range 1.460 - 6.790
Shares Outstanding 270,990,987
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Agenus Q1 Earnings
Agenus (NASDAQ:AGEN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-54.76%
-54.76%
1 Month
-30.84%
-30.84%
3 Month
-38.43%
-38.43%
6 Month
-55.01%
-55.01%
1 Year
-62.44%
-62.44%

More News

Read More
Looking Into Agenus's Return On Capital Employed
Via Benzinga
41 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
Recap: Agenus Q4 Earnings
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
Via Benzinga
Agenus inc (AGEN) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types
Via Benzinga
Why Agenus Was Rising High on Tuesday
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
35 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Via Benzinga
Here's Why Agenus Stock Is Getting Hammered Today
Via The Motley Fool
55 Biggest Movers From Friday
Via Benzinga
Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Via Benzinga
Why Agenus Fell by Over 4% on Monday
Via The Motley Fool
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Via Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Highs On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.